Breaking News: ALS Awareness Month Has Changed — to ALS Action Month

We are a 100% all-volunteer 501(c)(3) non-profit charity. No one takes a paycheck here and there are no administrative costs. That means 100% of all funds raised by the R.A.S.C.A.L.S. Foundation go directly to fighting ALS.

The money goes to fund promising treatment research and development. It helps with ALS family assistance, such as our annual Higher Education Scholarship program.

Categories: 501(c)(3) Non-Profit, ALS Community News, ALS Families, ALS News, Caretakers  |  Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS charity, ALS community, ALS cure, ALS diagnosis, ALS donations, ALS funding, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig's disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis  |  No comments

110% Gratitude to All Our Volunteers

April marks National Volunteer Month. This observance holds very special meaning for all of us here at the Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.). That’s because we are a 100% all-volunteer 501(c)(3) non-profit charity. There are no administrative costs.
That means no salaries, payments, or perks for anyone. Out-of-pocket expenses truly means out of our [...]

Categories: 501(c)(3) Non-Profit, ALS Community News, ALS Families, ALS News, RASCALS Foundation News, Treatments  |  Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS community, ALS cure, ALS diagnosis, ALS diagnostics, ALS donations, ALS funding, ALS medical care, ALS research, ALS research funding, ALS treatments, ALS volunteers, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig's disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis  |  No comments

Results of NurOwn™ Clinical Trial Suggest Efficacy in ALS Patients

Data Indicate Initial Clinical Benefit in Overall Clinical and Respiratory Function
NEW YORK, NY and PETACH TIKVAH, ISRAEL, March 21, 2013 — BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company’s NurOwn™ technology in 12 ALS patients. NurOwn [...]

Categories: ALS News, Clinical Trials, Research News, Technology, Treatments  |  Tags: Alon Natanson, ALS, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Analysis of 12 Patients with Amyotrophic Lateral Sclerosis (ALS) Treated with Autologous Differentiated Mesenchymal Stem Cells: a Phase I/II Clinical Trial, Annual Meeting of the American Academy of Neurology, Bob Stehlin, BrainStorm Cell Therapeutics, Brainstorm Cell Therapeutics Inc., Dimitrios Karussis, Hadassah Medical Center, Mesenchymal Stem Cells ALS, MSC-NTF ALS, NurOwn, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis  |  No comments

With A.L.S. in Family, Chief at Bloomberg Joins Fight

At a time when scientists are making rapid gains in the genetic roots of many diseases, Mr. Doctoroff, a former deputy mayor and private equity investor, is working with Mayor Michael R. Bloomberg and a private equity director, David M. Rubenstein, to put together a $25 million package of donations to support research to try to cure this rare and usually fatal degenerative neurological illness.

Categories: ALS Community News, ALS News, Research News  |  Tags: A.L.S. Association, ALS, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bloomberg L.P., Bloomberg Philanthropies, Bob Stehlin, C9ORF72, Carlyle Group, Columbia University, Daniel L. Doctoroff, David M. Rubenstein, Franklin & Marshall College, Johns Hopkins, Lou Gehrig's disease, Martin Doctoroff, Mayor Michael R. Bloomberg, PALS, Patricia E. Harris, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Target A.L.S.  |  No comments

Study Funded by The ALS Association Finds Neurons Can Be Reprogrammed to Take on New Identities

In work supported by The ALS Association and funded through The Milton Safenowitz Post-Doctoral Fellowship Program, researchers have for the first time reprogrammed a neuron from one type into another and have done so in a living organism. The finding will help scientists better understand how to control neuronal development and may one day aid in treating diseases in which neurons die, such as amyotrophic lateral sclerosis (ALS). The study was published in the journal Nature Cell Biology.

Categories: ALS News, Research News, Technology, Treatments  |  Tags: ALS, ALS Association, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Caroline Rouaux, cortex neuron ALS, corticofugal projection neurons ALS, corticospinal motor neurons ALS, Department of Stem Cell and Regenerative Biology at Harvard University in Cambridge, Greater New York Chapter of The ALS Association, Lou Gehrig's disease, Lucie Bruijn, National Institute of Health and Medical Research (INSERM) in Strasbourg, Nature Cell Biology, New York Stem Cell Foundation-Robertson Investigator Paola Arlotta\, PALS, Paola Arlotta, RASCALS Foundation, reprogrammed neuron ALS, Robert A. Stehlin Campaign for ALS, Rouaux The Milton-Safenowitz Post-Doctoral Fellowship, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, The Milton Safenowitz Post-Doctoral Fellowship Program  |  No comments

ALS Community Tells FDA ‘We Have No Time To Waste’; Urges Changes in Trial Design and Review Process

Because of the relentless effects of ALS, a diverse group of ALS voices — patients, families, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, clinical trials and standards of care.

Categories: Clinical Trials, Research News, Treatments  |  Tags: a diverse group of ALS voices — patients, ALS, ALS clinical trials, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS survivor Robert Anderson, ALS treatments, amyotrophic lateral sclerosis, Because of the relentless effects of ALS, Bob Stehlin, clinical trials and standards of care., Dr. Jonathan Glass, families, fast-track trials ALS, FDA, FDA ALS, Food and Drug Administration, Lou Gehrig's disease, MDA Senior Vice President of Advocacy Annie Kennedy, MDA/ALS Center of Hope in Philadelphia, MDA/ALS Clinic at Methodist Neurological Institute in Houston, Muscular Dystrophy Association MDA, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, Sara M. Feldman, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stan Appel, Steven M. Derks  |  No comments

Western University Researchers Identify New Genetic Mutation for ALS

Strong’s team is convinced ALS is a disorder of RNA metabolism. RNA is the intermediary or messenger between genes and the protein being made. This new protein appears to play a critical role. “Every time we look at a cell degenerating, this particular protein was deposited abnormally in the cell. It was a common denominator,” explains Strong, who is also the Dean of Schulich Medicine & Dentistry. “Working with Dr. Rob Hegele at Robarts, we found there was a genetic mutation in the gene coding for this protein. So it’s a huge discovery.”

Categories: Research News, Treatments  |  Tags: ALS, ALS community, ALS cure, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, ARHGEF28 gene ALS, Bob Stehlin, Canada ALS, Dr. Michael Strong ALS, Dr. Rob Hegele, Lou Gehrig's disease, PALS, RASCALS Foundation, RNA metabolism ALS, Robarts Research Institute, Robert A. Stehlin Campaign for ALS, Schulich School of Medicine & Dentistry, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Western University in London, World Federation of Neurology Research Group on Motor Neuron Disease  |  No comments

‘No White Flags’: Steve Gleason Builds Movement Against ALS

“I believe happiness is a choice. Some days it is a very difficult choice,” he says. “This is true for everyone. I look at the human life like an experiment. Every new moment, every new experience, tragic or otherwise, is an opportunity to gain a more accurate perspective and helps lead me to clarity.”

Categories: 501(c)(3) Non-Profit, Caretakers, Clinical Trials, Research News, Technology, Treatments  |  Tags: 501(c)(3) ALS charity, Aaron Rodgers, ALS Awareness Month, ALS charity, ALS community, ALS cure, ALS funding, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, chronic traumatic encephalopathy, chronic traumatic encephalopathy (CTE), Drew Brees, eye-tracking software ALS, global philanthropy JPMorgan Chase, Jay Rink, Jeff Duncan, Lake Pontchartrain, Lois Backon, Lou Gehrig's disease, Michel Gleason, Mike McCarthy, New Orleans Saints, O.J. Brigance, PALS, Paul Varisco and the Milestones, RASCALS Foundation, Ray Lewis, Rick Crozier, Rivers Gleason, Robert A. Stehlin Campaign for ALS, Scott Fujita, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stephen Jackson, Steve Gleason, Steve Gleason No White Flags, Super Bowl, Super Bowl Host Committee legacy project, Team Gleason, Team Gleason Experiment, Team Gleason House, UN Social Innovation Summit, USA Today Sports, Vinnie Varisco  |  No comments

NFL Players and Coaches Come Together for New Team Gleason ALS Message

# # #
The Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.) is an all-volunteer 501(c)(3) charity. 100% of all funds raised go to building awareness, treatment research and development, plus ALS family assistance. There are no administrative costs.
Contributions are tax-deductible.
You may also be interested in visiting the RASCALS Store.
The material presented here is for informational purposes [...]

Categories: 501(c)(3) Non-Profit, Caretakers, Research News, Technology, Treatments  |  Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS charity, ALS community, ALS cure, ALS donations, ALS funding, ALS medical care, ALS research, ALS research funding, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, breakthrough, Lou Gehrig's disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Steve Gleason, Team Gleason  |  No comments

Stem Cells May Hold Promise for Lou Gehrig’s Disease (ALS)

The study found that stem cell transplantation significantly extended the lifespan of the mice by 20 days and improved their neuromuscular function by 15 percent. “Our study shows promise for testing stem cell transplantation in human clinical trials,” said Corti.

Categories: Research News, Treatments  |  Tags: ALS, ALS community, ALS cure, ALS funding, ALS mice, ALS research, ALS research funding, ALS treatments, American Academy of Neurology, amyotrophic lateral sclerosis, AriSLA, Bob Stehlin, effective cell-based treatment for ALS, induced pluripotent stem cells (iPSCs) ALS, iPSC, Italian Foundation for Research on Amyotrophic Lateral Sclerosis, Lou Gehrig's disease, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stefania Corti, Stem cell transplants, Stem cell transplants ALS, University of Milan  |  No comments